- Home
- XAIR vs PHGE Comparison
XAIR vs PHGE Comparison
Compare XAIR & PHGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XAIR
- PHGE
- Stock Information
- Founded
- XAIR 2011
- PHGE 2015
- Country
- XAIR United States
- PHGE Israel
- Employees
- XAIR N/A
- PHGE N/A
- Industry
- XAIR Medical/Dental Instruments
- PHGE Biotechnology: Pharmaceutical Preparations
- Sector
- XAIR Health Care
- PHGE Health Care
- Exchange
- XAIR Nasdaq
- PHGE Nasdaq
- Market Cap
- XAIR 17.0M
- PHGE 15.5M
- IPO Year
- XAIR N/A
- PHGE N/A
- Fundamental
- Price
- XAIR $2.36
- PHGE $0.57
- Analyst Decision
- XAIR Strong Buy
- PHGE Strong Buy
- Analyst Count
- XAIR 1
- PHGE 1
- Target Price
- XAIR $11.00
- PHGE $15.00
- AVG Volume (30 Days)
- XAIR 241.3K
- PHGE 378.4K
- Earning Date
- XAIR 11-10-2025
- PHGE 11-13-2025
- Dividend Yield
- XAIR N/A
- PHGE N/A
- EPS Growth
- XAIR N/A
- PHGE N/A
- EPS
- XAIR N/A
- PHGE N/A
- Revenue
- XAIR $4,782,000.00
- PHGE N/A
- Revenue This Year
- XAIR $261.11
- PHGE N/A
- Revenue Next Year
- XAIR $151.82
- PHGE N/A
- P/E Ratio
- XAIR N/A
- PHGE N/A
- Revenue Growth
- XAIR 168.20
- PHGE N/A
- 52 Week Low
- XAIR $2.02
- PHGE $0.34
- 52 Week High
- XAIR $13.52
- PHGE $1.16
- Technical
- Relative Strength Index (RSI)
- XAIR 46.14
- PHGE 55.95
- Support Level
- XAIR $2.52
- PHGE $0.57
- Resistance Level
- XAIR $2.75
- PHGE $0.65
- Average True Range (ATR)
- XAIR 0.15
- PHGE 0.05
- MACD
- XAIR -0.01
- PHGE 0.00
- Stochastic Oscillator
- XAIR 10.64
- PHGE 64.16
About XAIR Beyond Air Inc.
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.
About PHGE BiomX Inc. COmmon Stock
BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).